Dynavax Technologies (DVAX +3%) moves up with the overall market today, shrugging off a...

|About: Dynavax Technologies Corpor... (DVAX)|By:, SA News Editor

Dynavax Technologies (DVAX +3%) moves up with the overall market today, shrugging off a less-than-stellar initiation at JPMorgan with a Neutral rating. The firm cites certain regulatory risks associated with DVAX's hepatitis B vaccine Heplisav. The stock dropped 47% in November after the FDA panel gave its decision that the drug's safety data was inadequate. Heplisav is an adjuvant vaccine that regulators say might cause autoimmune diseases.